EyePoint Pharmaceuticals Inc. (PV3B)

Overview

EyePoint Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for patients suffering from serious retinal diseases. Utilizing its proprietary bioerodible Durasert E technology, the company endeavors to offer sustained intraocular drug delivery solutions. Originating as pSivida Corp. before rebranding to EyePoint Pharmaceuticals in March 2018, the company has been advancing its mission since its inception in 1987. Headquartered in Watertown, Massachusetts, EyePoint Pharmaceuticals is committed to leveraging its technological innovations to address the unmet medical needs of patients with retinal disorders.

Products and Services

• EYP-1901

  This lead product candidate represents a significant advancement in the treatment of VEGF-mediated retinal diseases. EYP-1901 combines vorolanib, a selective and patent-protected tyrosine kinase inhibitor, with EyePoint's Durasert E technology for sustained delivery. Currently, it is in Phase 2 clinical trials targeting conditions such as wet age-related macular degeneration (wet AMD), non-proliferative diabetic retinopathy (NPDR), and diabetic macular edema (DME). This investigational treatment underscores the company's commitment to addressing the complexities of retinal diseases through innovative sustained delivery mechanisms.

• EYP-2301

  Another promising pipeline program, EYP-2301, harnesses the Durasert E technology to formulate a TIE-2 agonist. This approach is aimed at improving outcomes in serious retinal diseases by potentially offering a novel mechanism of action. While still under development, EYP-2301 exemplifies EyePoint Pharmaceuticals' ongoing exploration of diverse therapeutic avenues to meet the varied challenges posed by retinal diseases.